US2008188796A1PendingUtilityA1

Closed-Loop Method for Controlling Insulin Infusion

Assignee: MEDTRONIC MINIMED INCPriority: Jun 3, 1999Filed: Apr 4, 2008Published: Aug 7, 2008
Est. expiryJun 3, 2019(expired)· nominal 20-yr term from priority
A61M 5/158G16H 20/17A61B 5/4839A61M 5/14244A61M 5/1723A61B 5/7242A61M 5/1582A61B 5/1495A61M 2005/1581A61B 5/14539A61B 5/14532A61B 5/6849A61M 2230/201A61M 2005/1726A61B 5/14865
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A closed loop infusion system controls the rate that fluid is infused into the body of a user. The closed loop infusion system includes a sensor system, a controller, and a delivery system. The sensor system includes a sensor for monitoring a condition of the user. The sensor produces a sensor signal, which is representative of the condition of the user. The sensor signal is used to generate a controller input. The controller uses the controller input to generate commands to operate the delivery system. The delivery system infuses a liquid into the user at a rate dictated by the commands from the controller. Preferably, the sensor system monitors the glucose concentration in the body of the user, and the liquid infused by the delivery system into the body of the user includes insulin.

Claims

exact text as granted — not AI-modified
1 .- 32 . (canceled) 
     
     
         33 . A method for calculating the amount of insulin to be infused into a body of a user, the method comprising:
 obtaining a blood glucose concentration of the user;   generating a controller input based on the blood glucose concentration; and   generating infusion calculations by a proportional plus, integral plus, derivative (PID) controller from the controller input using at least one preset controller gain;   wherein the at least one preset controller gain is selected such that the infusion commands generated by the PID controller infuses insulin into the body of the user in response to the glucose concentration at a rate similar to a rate that beta cells would release insulin in an individual with a healthy normally functioning pancreas; and   wherein the an automatic blood withdrawal system is used to obtain the blood glucose concentration of the user.   
     
     
         34 . The method according to  claim 33 , further comprising:
 infusing insulin based on the infusion calculations from the PID controller;   wherein the insulin is infused through an IV catheter connected to the body of the user.   
     
     
         35 . The method according to  claim 33 , wherein the at least one preset controller gain includes at least one tuning parameter that further modifies the commands generated by the PID controller to create an insulin concentration profile that more closely resembles the insulin concentration profile that would be generated by the release of insulin by beta cells in an individual with a healthy normally functioning pancreas. 
     
     
         36 . The method according to  claim 35 , wherein the at least one tuning parameter is an integrator leak. 
     
     
         37 . The method according to  claim 35 , wherein the at least one tuning parameter is a lead/lag compensator. 
     
     
         38 . The method according to  claim 35 , wherein the at least one tuning parameter is an integrator clip. 
     
     
         39 . The method according to  claim 35 , wherein the at least one tuning parameter is a feedback of predicted plasma insulin. 
     
     
         40 . The method according to  claim 33 , wherein the at least one preset controller gain is selected by a method that includes the step of measuring an insulin response of at least one individual with a healthy normally functioning pancreas and calculating the at least one controller gain that causes the infusion commands to generally match the insulin response of the at least one individual. 
     
     
         41 . The method according to  claim 33 , wherein the PID controller is a bilinear PID controller.

Join the waitlist — get patent alerts

Track US2008188796A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.